DE60142351D1 - TREATMENT OF HYPOACTIVE MYOKARD AND DIABETIC HEART MYOPATHY WITH A GLP-1 PEPTIDE - Google Patents
TREATMENT OF HYPOACTIVE MYOKARD AND DIABETIC HEART MYOPATHY WITH A GLP-1 PEPTIDEInfo
- Publication number
- DE60142351D1 DE60142351D1 DE60142351T DE60142351T DE60142351D1 DE 60142351 D1 DE60142351 D1 DE 60142351D1 DE 60142351 T DE60142351 T DE 60142351T DE 60142351 T DE60142351 T DE 60142351T DE 60142351 D1 DE60142351 D1 DE 60142351D1
- Authority
- DE
- Germany
- Prior art keywords
- glp
- hibernating
- myocardium
- myokard
- hypoactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Hibernating myocardium is characterized by viable myocardium with impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinepherine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines lead to cardiomyopathy in patients with diabetes. GLP-1 reduces plasma norepinepherine levels, and it thus is useful in a method of treating hibernating myocardium or diabetic cardiomyopathy.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24183400P | 2000-10-20 | 2000-10-20 | |
US24213900P | 2000-10-23 | 2000-10-23 | |
US24523400P | 2000-11-03 | 2000-11-03 | |
PCT/US2001/032559 WO2002034285A2 (en) | 2000-10-20 | 2001-10-22 | Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60142351D1 true DE60142351D1 (en) | 2010-07-22 |
Family
ID=27399525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60142351T Expired - Lifetime DE60142351D1 (en) | 2000-10-20 | 2001-10-22 | TREATMENT OF HYPOACTIVE MYOKARD AND DIABETIC HEART MYOPATHY WITH A GLP-1 PEPTIDE |
Country Status (11)
Country | Link |
---|---|
US (3) | US6894024B2 (en) |
EP (1) | EP1330261B1 (en) |
JP (1) | JP4480329B2 (en) |
AT (1) | ATE470448T1 (en) |
AU (2) | AU775663B2 (en) |
CA (1) | CA2395165C (en) |
DE (1) | DE60142351D1 (en) |
ES (1) | ES2347137T3 (en) |
MX (1) | MXPA02006118A (en) |
NZ (1) | NZ519752A (en) |
WO (1) | WO2002034285A2 (en) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429197B1 (en) | 1998-10-08 | 2002-08-06 | Bionebraska, Inc. | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
US7259136B2 (en) * | 1999-04-30 | 2007-08-21 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating peripheral vascular disease |
US20090175821A1 (en) * | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US20030113301A1 (en) * | 1999-07-23 | 2003-06-19 | Albert Edge | Muscle cells and their use in cardiac repair |
EP1463751B1 (en) | 2001-12-21 | 2013-05-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050260259A1 (en) * | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
WO2003072143A1 (en) * | 2002-02-27 | 2003-09-04 | Pharmain, Ltd. | Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
US7635463B2 (en) * | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
JP2005535569A (en) * | 2002-04-04 | 2005-11-24 | ノボ・ノルデイスク・エー/エス | GLP-1 agonists and cardiovascular complications |
US6861553B2 (en) | 2002-07-03 | 2005-03-01 | Teva Pharmaceuticals Industries Ltd. | Process for preparing nateglinide and intermediates thereof |
US7358390B2 (en) | 2002-07-18 | 2008-04-15 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
US7420084B2 (en) | 2002-07-18 | 2008-09-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
US7534913B2 (en) | 2002-07-18 | 2009-05-19 | Teva Pharmaceutica Industries Ltd. | Crystalline form of nateglinide |
US7148376B2 (en) | 2002-07-18 | 2006-12-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
US7192922B2 (en) * | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
WO2004056313A2 (en) * | 2002-12-17 | 2004-07-08 | Amylin Pharmaceuticals, Inc. | Prevention and treatment of cardiac arrhythmias |
US20040209803A1 (en) * | 2002-12-19 | 2004-10-21 | Alain Baron | Compositions for the treatment and prevention of nephropathy |
US7790681B2 (en) * | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
AU2005211725B2 (en) | 2004-02-09 | 2010-07-15 | Human Genome Sciences, Inc. | Albumin fusion proteins |
BRPI0510117A (en) * | 2004-04-23 | 2007-09-25 | Conjuchem Biotechnologies Inc | method for purification of albumin conjugates |
EP1888103B1 (en) * | 2005-04-11 | 2012-03-21 | Amylin Pharmaceuticals, Inc. | Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling |
CN101258163B (en) | 2005-06-30 | 2013-08-21 | 益普生制药股份有限公司 | Glp-1 pharmaceutical compositions |
US8039432B2 (en) * | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
TWI402273B (en) * | 2005-12-09 | 2013-07-21 | Vectus Biosystems Ltd | Vip fragments and methods of use |
CN101365490B (en) | 2005-12-19 | 2012-11-28 | 药明公司 | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same |
WO2007071068A1 (en) * | 2005-12-22 | 2007-06-28 | Conjuchem Biotechnologies Inc. | Process for the production of preformed conjugates of albumin and a therapeutic agent |
US7960336B2 (en) * | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
US8563527B2 (en) * | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
CA2708762A1 (en) * | 2007-12-11 | 2009-06-18 | Conjuchem Biotechnologies Inc. | Formulation of insulinotropic peptide conjugates |
US20090176892A1 (en) * | 2008-01-09 | 2009-07-09 | Pharmain Corporation | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
EP2334234A4 (en) | 2008-09-19 | 2013-03-20 | Tandem Diabetes Care Inc | Solute concentration measurement device and related methods |
ES2620610T3 (en) | 2008-12-10 | 2017-06-29 | Glaxosmithkline Llc | Albiglutide pharmaceutical compositions |
EP2216042A1 (en) | 2009-02-09 | 2010-08-11 | Ipsen Pharma S.A.S. | GLP-1 analogues pharmaceutical compositions |
US20100332417A1 (en) * | 2009-06-02 | 2010-12-30 | Targeted Molecular Diagnostics, Llc | Methods for the detection and quantitation of the p95 component of her2/neu (erbb2) |
CA2921304C (en) | 2009-07-30 | 2018-06-05 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
EP2525809B1 (en) * | 2010-01-20 | 2016-08-03 | Zealand Pharma A/S | Glucagon-glp1 dual agonists for use in the treatment of cardiac conditions |
US9089538B2 (en) | 2010-04-27 | 2015-07-28 | Zealand Pharma A/S | Peptide conjugates of GLP-1 receptor agonists and gastrin and their use |
WO2011140176A1 (en) | 2010-05-04 | 2011-11-10 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
BR112012033295A2 (en) | 2010-07-02 | 2016-10-11 | Angiochem Inc | d-amino acid-containing short polypeptides for therapeutic conjugates and their use |
CN104144704B (en) | 2011-11-03 | 2018-03-23 | 西兰制药公司 | The receptor agonist peptides gastrin conjugates of GLP 1 |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
MY170671A (en) | 2012-07-23 | 2019-08-26 | Zealand Pharma As | Glucagon analogues |
TWI608013B (en) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | Glucagon analogues |
UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
PL2934567T3 (en) | 2012-12-21 | 2018-10-31 | Sanofi | Exendin-4 derivatives as dual glp1/gip- or trigonal glp1/gip/glucagon agonists |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
PT3057984T (en) | 2013-10-17 | 2018-10-24 | Boehringer Ingelheim Int | Acylated glucagon analogues |
CA2929459C (en) | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
CN105829339B (en) | 2013-11-06 | 2021-03-12 | 西兰制药公司 | glucagon-GLP-1-GIP triple agonist compounds |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201609799A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Dual GLP-1/GIP receptor agonists |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
WO2016066744A2 (en) | 2014-10-29 | 2016-05-06 | Zealand Pharma A/S | Gip agonist compounds and methods |
CN107636010B (en) | 2015-04-16 | 2021-10-01 | 西兰制药公司 | Acylated glucagon analogues |
AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
TW201706291A (en) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
US10492141B2 (en) | 2015-11-17 | 2019-11-26 | Tandem Diabetes Care, Inc. | Methods for reduction of battery usage in ambulatory infusion pumps |
RU2753193C2 (en) | 2016-12-09 | 2021-08-12 | Зилэнд Фарма А/С | Acylated double agonists of glp-1/glp-2 |
WO2019067511A1 (en) * | 2017-09-27 | 2019-04-04 | The University Of Toledo | Materials and methods useful to induce cancer cell death via methuosis or autophagy or a combination thereof |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196196A (en) | 1978-06-19 | 1980-04-01 | Tiholiz Ivan C | Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states |
US4880911A (en) | 1982-03-19 | 1989-11-14 | G. D. Searle & Co. | Fused polypeptides and methods for their detection |
US4728609A (en) | 1983-01-10 | 1988-03-01 | Hoffmann-La-Roche Inc. | Recombinant growth hormone releasing factor |
US5155214A (en) | 1984-03-05 | 1992-10-13 | The Salk Institute For Biological Studies | Basic fibroblast growth factor |
US4761375A (en) | 1984-05-08 | 1988-08-02 | Genetics Institute, Inc. | Human interleukin-2 cDNA sequence |
US4868113A (en) | 1986-03-03 | 1989-09-19 | Rorer Biotechnology, Inc. | Recombinant DNA vector encoding human endothelial cell growth factor |
US5340725A (en) | 1986-10-09 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Expression vector for insulin-like growth factor I and method of production |
PT87133B (en) | 1987-04-02 | 1992-07-31 | Amrad Corp Ltd | METHOD OF PURIFICATION OF THE LEUKEMIA INHIBITOR FACTOR (LIF) AND PHARMACEUTICAL COMPOSITIONS CONTAINING POLIPEPTIDES WITH LIF ACTIVITY |
US5082774A (en) | 1988-08-30 | 1992-01-21 | The General Hospital Corporation | Recombinant human nerve growth factor |
US5102789A (en) | 1989-03-15 | 1992-04-07 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Production of epideramal growth factor in pichia pastoris yeast cells |
US5599907A (en) | 1989-05-10 | 1997-02-04 | Somatogen, Inc. | Production and use of multimeric hemoglobins |
US6204259B1 (en) | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
US5574138A (en) | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5935924A (en) | 1994-04-15 | 1999-08-10 | Genentech, Inc. | Treatment of congestive heart failure |
GB9409496D0 (en) | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
JP3314938B2 (en) | 1995-06-06 | 2002-08-19 | ファイザー・インコーポレーテッド | Substituted N- (indole-2-carbonyl) -glycinamides and derivatives as glycogen phosphorylase inhibitors |
US5976082A (en) | 1996-06-17 | 1999-11-02 | Smithkline Beecham Corporation | Method for identifying at risk patients diagnosed with congestive heart failure |
US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
US5955594A (en) | 1997-04-30 | 1999-09-21 | Mishra; Lopa | Nucleic acids encoding proteins for early liver development |
JP4677095B2 (en) * | 1998-02-13 | 2011-04-27 | アミリン・ファーマシューティカルズ,インコーポレイテッド | Inotropic and diuretic effects of exendin and GLP-1 |
US7259136B2 (en) * | 1999-04-30 | 2007-08-21 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating peripheral vascular disease |
US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
US6235481B1 (en) * | 1998-10-21 | 2001-05-22 | Arch Development Corporation & Board Of Regents | Polynucleotides encoding calpain 10 |
ES2302390T3 (en) * | 1998-12-07 | 2008-07-01 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | GLP-1 ANALOGS |
US6506724B1 (en) * | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
DK1088824T3 (en) * | 1999-09-30 | 2004-04-13 | Pfizer Prod Inc | Bicyclic pyrrolylamides as glycogen phosphorylase inhibitors |
CO5271699A1 (en) * | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | PROCEDURE FOR THE TREATMENT OF CARDIOMIOPATIA USING INHIBITORS OF THE GLUCOGENO FOSFORILASA |
EP1127882A1 (en) * | 2000-01-25 | 2001-08-29 | Pfizer Products Inc. | Tetrazole compounds as thyroid receptor ligands |
US6706689B2 (en) * | 2000-05-19 | 2004-03-16 | Amylin Pharmaceuticals, Inc. | Treatment of acute coronary syndrome with GLP-1 |
US7192922B2 (en) * | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
US8263545B2 (en) * | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
-
2001
- 2001-10-22 NZ NZ519752A patent/NZ519752A/en not_active IP Right Cessation
- 2001-10-22 MX MXPA02006118A patent/MXPA02006118A/en active IP Right Grant
- 2001-10-22 AT AT01983169T patent/ATE470448T1/en not_active IP Right Cessation
- 2001-10-22 CA CA2395165A patent/CA2395165C/en not_active Expired - Fee Related
- 2001-10-22 JP JP2002537336A patent/JP4480329B2/en not_active Expired - Fee Related
- 2001-10-22 DE DE60142351T patent/DE60142351D1/en not_active Expired - Lifetime
- 2001-10-22 US US09/982,978 patent/US6894024B2/en not_active Expired - Fee Related
- 2001-10-22 EP EP01983169A patent/EP1330261B1/en not_active Expired - Lifetime
- 2001-10-22 AU AU14618/02A patent/AU775663B2/en not_active Ceased
- 2001-10-22 ES ES01983169T patent/ES2347137T3/en not_active Expired - Lifetime
- 2001-10-22 WO PCT/US2001/032559 patent/WO2002034285A2/en active IP Right Grant
-
2004
- 2004-11-11 AU AU2004229049A patent/AU2004229049C1/en not_active Ceased
- 2004-12-08 US US11/007,938 patent/US20050096276A1/en not_active Abandoned
-
2010
- 2010-11-12 US US12/945,702 patent/US8551947B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6894024B2 (en) | 2005-05-17 |
EP1330261B1 (en) | 2010-06-09 |
JP2004512311A (en) | 2004-04-22 |
ES2347137T3 (en) | 2010-10-26 |
US20050096276A1 (en) | 2005-05-05 |
AU1461802A (en) | 2002-05-06 |
AU2004229049C1 (en) | 2008-12-11 |
US20020146405A1 (en) | 2002-10-10 |
MXPA02006118A (en) | 2004-08-23 |
CA2395165A1 (en) | 2002-05-02 |
AU2004229049A1 (en) | 2004-12-09 |
NZ519752A (en) | 2005-04-29 |
WO2002034285A3 (en) | 2003-05-15 |
WO2002034285A2 (en) | 2002-05-02 |
JP4480329B2 (en) | 2010-06-16 |
US8551947B2 (en) | 2013-10-08 |
EP1330261A2 (en) | 2003-07-30 |
US20120302501A1 (en) | 2012-11-29 |
AU775663B2 (en) | 2004-08-12 |
ATE470448T1 (en) | 2010-06-15 |
AU2004229049B2 (en) | 2007-11-01 |
CA2395165C (en) | 2012-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60142351D1 (en) | TREATMENT OF HYPOACTIVE MYOKARD AND DIABETIC HEART MYOPATHY WITH A GLP-1 PEPTIDE | |
Hon et al. | Bridge to recovery with the use of left ventricular assist device and clenbuterol | |
ES2167427T3 (en) | COMBINATION OF HORMONE OF GROWTH AND FACTOR OF SIMILAR GROWTH TO INSULIN IN THE TREATMENT OF CARDIAC INSUFFICIENCY. | |
WO2008030547B1 (en) | Intramyocardial patterning for global cardiac resizing and reshaping | |
Mann | Recent insights into the role of tumor necrosis factor in the failing heart | |
Fleck et al. | Modern collagen wound dressings: function and purpose | |
RU2005102593A (en) | APPLICATION OF HMGB1 IN TREATMENT OF TISSUE DAMAGE AND / OR TO PROMOTE TISSUE RECOVERY | |
Kakarla et al. | Sustainable electricity generation and ammonium removal by microbial fuel cell with a microalgae assisted cathode at various environmental conditions | |
EA200400984A1 (en) | COMPOSITIONS AND METHODS OF MODULING CONNEX KEMIXANALS | |
PE20011363A1 (en) | PEPTIDE-1 ANALOGUES LIKE GLUCAGON | |
CY1108769T1 (en) | INSPECTIONS OF DIPLOMATIC CONDITION IV TO REDUCE THE YEAR OF WEIGHT GROWTH | |
Evans et al. | Modulation of myocardial relaxation by basal release of endothelin from endocardial endothelium | |
NI201500057A (en) | METHODS TO REDUCE RISKS ASSOCIATED WITH HEART FAILURE AND ASSOCIATED FACTORS | |
AR114392A1 (en) | TREATMENT OF PATIENTS WITH CLASSIC FABRY DISEASE | |
Gesser | Cardiac force-interval relationship, adrenaline and sarcoplasmic reticulum in rainbow trout | |
Widgerow | Bioengineered skin substitute considerations in the diabetic foot ulcer | |
García et al. | Abnormal cardiac wall motion and early matrix metalloproteinase activity | |
Gajewski et al. | The human body as an energetic hybrid? New perspectives for chronic disease treatment? | |
Carnevale et al. | Effects of hypoxic acclimation, muscle strain, and contraction frequency on nitric oxide-mediated myocardial performance in steelhead trout (Oncorhynchus mykiss) | |
ECSP22049399A (en) | ARTIFICIAL ADJUVANT VECTOR CELL CONTAINING NY?ESO?1 FOR USE IN THE TREATMENT OF CANCER | |
MX2023000780A (en) | Composition for preventing or treating osteoarthritis, comprising mesenchymal stem cell expressing tumor necrosis factor-inducible gene 6. | |
Shelke et al. | Natriuretic peptide system in hypertension: current understandings of its regulation, targeted therapies and future challenges | |
Yan et al. | Insulin-like growth factor-1 in myocardial ischemia-reperfusion injury: A review | |
Sarai et al. | A simulation study to rescue the Na+/Ca2+ exchanger knockout mice | |
AR028641A1 (en) | METHODS FOR PREVENTION OF ULCERAS AND IMPROVEMENT OF PHYSIOLOGICAL PERFORMANCE |